Dr. André-Guy Martin is a clinical radio-oncologist and brachytherapy specialist with the CHU de Québec radio-oncology Department. He is also a research associate at the Centre de recherche du CHU de Québec-Laval University, Oncology Axis, affiliated with the Laval University Cancer Research Center.
Having graduated with a PhD in radio-oncology from Laval University in 2002, he went on to train in brachytherapy and obtained a Fellowship in Brachytherapy from the Brigham and Women’s Hospital of the prestigious Harvard Medical School in Boston, Massachusetts, U.S.A. He also completed a master’s degree in experimental medicine (MSc) focusing on prostate brachytherapy through the I-125 implant. He has been practicing brachytherapy since, and is mainly interested in urological and digestive sites (brachytherapy of the esophagus and rectum).
His area of interest in research focuses mainly on imagery-guided, concentrated brachytherapy. Along with his team, he has added the new modalities of magnetic resonance imagery and is working on setting up an automated guidance system. Thanks to his previous training in pharmacology, he has developed new pharmacotherapeutic avenues (cytoreduction) to optimize the brachytherapy approach. He contributes to and locally directs the NRG protocols.
Very involved in his area of research, he is the co-editor of the Contemporary Journal of Brachytherapy. On the provincial level, he is treasurer for l’Association des radio-oncologues du Québec. Internationally, he also supports the Groupe Francophone de Radiothérapie en Urologie.
Hôtel-Dieu de Québec
11 Côte du Palais, Bureau 3342
Canada G1R 2J6
Data not available
Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy.Journal Article
Int J Radiat Oncol Biol Phys, 97 (3), pp. 606-615, 2017, ISSN: 0360-3016.
Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.Journal Article
Clin Oncol (R Coll Radiol), 29 (3), pp. 161-170, 2017, ISSN: 0936-6555.
External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.Journal Article
Can Urol Assoc J, 11 (3-4), pp. 94-100, 2017, ISSN: 1911-6470.
High-dose-rate brachytherapy boost for prostate cancer treatment: Different combinations of hypofractionated regimens and clinical outcomes.Journal Article
Radiother Oncol, 124 (1), pp. 49-55, 2017, ISSN: 0167-8140.
Supplementary data: External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancerJournal Article
Can Urol Assoc J, 11 (3-4), pp. E126-E127, 2017, ISSN: 1911-6470.
Image-guided high-dose-rate brachytherapy boost to the dominant intraprostatic lesion using multiparametric magnetic resonance imaging including spectroscopy: Results of a prospective study.Journal Article
Brachytherapy, 15 (6), pp. 746-751, 2016, ISSN: 1538-4721.
Image-Guided High-Dose-Rate (HDR) Boost Localization Using MRI/MR Spectroscopy: A Correlation Study with Biopsy.Journal Article
Cureus, 8 (9), pp. e795, 2016, ISSN: 2168-8184.
Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.Journal Article
Radiother Oncol, 118 (1), pp. 141-7, 2016, ISSN: 0167-8140.
Does prostate volume has an impact on biochemical failure in patients with localized prostate cancer treated with HDR boost?Journal Article
Radiother Oncol, 121 (2), pp. 304-309, 2016, ISSN: 0167-8140.
Prospective Phase II Trial of Once-weekly Hypofractionated Radiation Therapy for Low-risk Adenocarcinoma of the Prostate: Late Toxicities and Outcomes.Journal Article
Clin Oncol (R Coll Radiol), 28 (6), pp. 386-92, 2016, ISSN: 0936-6555.